tbuckley/cabot-search huggingface dataset:
Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection
Authors: Marianne Martinello, Chloe Orkin, Graham Cooke, Sanjay Bhagani, Edward Gane, Ranjababu Kulasegaram, David Shaw, Elise Tu, Kathy Petoumenos, Philippa Marks, Jason Grebely, Gregory J. Dore, Mark Nelson, Gail V. Matthews
Journal: Hepatology (2019)

Among treatment-naive individuals with chronic hepatitis C viral (HCV) infection and without cirrhosis, glecaprevir/pibrentasvir for 8 weeks is recommended. The aim of this analysis was to evaluate the efficacy of glecaprevir/pibrentasvir for 6 weeks in people with acute and recent HCV infection.In this open-label, single-arm, multicenter, international pilot study, adults with recent HCV (duration of infection < 12 months) received glecaprevir/pibrentasvir 300/120 mg daily for 6 weeks. Primary infection was defined by first positive anti-HCV antibody and/or HCV RNA within 6 months of enrollment and either acute clinical hepatitis within the past 12 months (symptomatic seroconversion illness or alanine aminotransferase > 10 × upper limit of normal) or anti-HCV antibody seroconversion within 18 months. Reinfection was defined as new positive HCV RNA within 6 months of enrollment and evidence of prior spontaneous or treatment-induced clearance. The primary endpoint was sustained virologic response at 12 weeks posttreatment (SVR12). Thirty men (median age 43 years, 90% men who have sex with men) received treatment, of whom 77% (n = 23) were human immunodeficiency virus-positive, 47% (n = 14) had ever injected drugs, and 13% (n = 4) had HCV reinfection. The majority had HCV genotype 1 (83%, n = 25), followed by genotype 4 (10%, n = 3) and genotype 3 (7%, n = 2). At baseline, median estimated duration of infection was 29 weeks (range 13, 52) and median HCV RNA was 6.2 log10 IU/mL (range 0.9, 7.7). SVR12 in the intention-to-treat and per-protocol populations was achieved in 90% (27/30) and 96% (27/28), respectively. There was one case of relapse, and there were two cases of nonvirological failure (death, n = 1; loss to follow-up, n = 1). No treatment-related serious adverse events were seen.Glecaprevir/pibrentasvir for 6 weeks was highly effective among people with acute and recent HCV infection, supporting further evaluation of shortened-duration pan-genotypic therapy in this setting.
Extreme Thrombocytosis: Influence of Care Setting and Likelihood of Occult Malignancy
Authors: Ronan W. Hsieh, Aishwarya Ravindran, C. Christopher Hook, Rajiv K. Pruthi, Ariela L. Marshall, Aneel A. Ashrani, Kebede H. Begna, Timothy G. Call, William J. Hogan, Mark R. Litzow, James D. Hoyer, Jennifer L. Oliveira, Prakash Vishnu, Ayalew Tefferi, Michelle A. Elliott, Aref Al-Kali, Alexandra P. Wolanskyj-Spinner, Ronald S. Go
Journal: Blood (2017)
P2.03-09 Arf6-Related Invasive Pathway Deteriorated Patients’ Prognosis in Mutant EGFR Lung Adenocarcinoma
Authors: T. Menju, M. Noguchi, S. Tamari, H. Ishikawa, R. Miyata, S. Nishikawa, K. Takahashi, A. Yoshizawa, H. Haga, H. Date
Journal: Journal of Thoracic Oncology (2019)
New tick-borne encephalitis virus hot spot in Northern Zealand, Denmark, October 2019
Authors: Charlotte N Agergaard, Maiken W Rosenstierne, René Bødker, Morten Rasmussen, Peter H S Andersen, Anders Fomsgaard
Journal: Eurosurveillance (2019)

During summer 2019, three patients residing by Tisvilde Hegn, Denmark were hospitalised with tick-borne encephalitis (TBE) after tick bites. A new TBE virus (TBEV) micro-focus was identified in tick nymphs collected around a playground in Tisvilde Hegn forest. Estimated TBEV prevalence was 8%, higher than in endemic areas around Europe. Whole genome sequencing showed clustering to a TBEV strain from Norway. This is the second time TBEV is found in Ixodes ricinus outside Bornholm, Denmark.
Expansion of umbilical cord blood mesenchymal stem cells
Authors: R. E. Peters, M. Heikenwälder, A. Knuth
Journal: Journal of Clinical Oncology (2009)

7103 Background: Umbilical cord blood (UCB) is known to harbor 2 major types of stem cells, the hematopoietic stem cells (HSC) &amp; the non-hematopoietic or mesenchymal stem cells (MSC). Under appropriate conditions, MSCs can give rise to cells of bone, fat, hepatic lineages, etc. Based on this potential, MSC hold promise for clinical applications in regenerative medicine. Methods: Stroma-free liquid culture: UCB cryopreserved mononuclear cells (MNC) were cultured in the presence of early growth factors: Flt-3 &amp; SCF (25ng/ml), MGDF (10ng/ml) &amp; human serum (10%). MNC derived adherent MSC were passaged at day 14 during HSC expansion &amp; after enriching in MesenCult medium. Results: We developed a technology to generate &amp; expand HSC &amp; stromal/ MSC from all UCB units (5/5) at the same time using one culture system (stroma-free liquid culture). Following repeated passages, MSC count increased 357- 600-folds &amp; CFU-Fibroblasts colonies (CFU-F) increased too (61–513 &amp; 648–697) after 10 and 20 passages respectively. We used the CFU-F assay to demonstrate MSC activity in stromal cell formation in vitro. Phenotypically, MSC were negative for hematopoietic antigens (CD45, CD34 &amp; CD14) &amp; MHC class-II but &gt;95% + for CD73, CD105, CD29, CD44 &amp; MHC class I. To demonstrate MSC differentiation capacity in vitro, cells were incubated in various induction media to differentiate into adipocytes (fat)), osteoblasts (bone) and hepatocytes (liver) at passage 5. Following induction, positive staining with oil red O for cells of adipocyte and with alkaline phosphatase for cells of osteoblsts lineages was observed. The identity of hepatocytes was verified by the characteristic hexagonal hepatocytic shape as well as albumin, cytokeratin (CK) 18 and CK14 expression, as assessed by flow cytometry. Our data were corroborated by RT-PCR analysis. Conclusions: MSC described herein exhibit in vitro properties of multipotent stem cells. The established, stroma-free culture system facilitates expansion of MSC from all tested UCB units. Our data underline that it will be possible in the future to substitutes properly differentiated hepatocytes which might lead to efficient applications in patients suffering from various end stage liver disease. No significant financial relationships to disclose.
Abstract 15215: Decreased Rates of Revascularization and Increased In-Hospital Mortality in Patients With Substance Use Disorders Admitted for Acute Coronary Syndromes
Authors: Shabatun J Islam, Howard J Cabral, Alice K Jacobs
Journal: Circulation (2018)

Introduction: Within the current opioid epidemic, the prevalence of substance use disorders (SUD) has been increasing. Concern has been raised that patients with SUD are less likely to receive guid...
P2.14-14 Comparison of Molecular Testing Modalities for Detection of NRG1 Rearrangements in Invasive Mucinous Adenocarcinoma
Authors: D. Trombetta, F. Fabrizio, P. Graziano, G. Rossi, M. Manzorra, A. Sparaneo, F. Cento, A. Rossi, M. Tiseo, L. Gnetti, M. Di Maio, E. Maiello, V. Fazio, L. Muscarella
Journal: Journal of Thoracic Oncology (2019)
OA01.01 Predictive Value of EBUS Strain Elastography in Mediastinal Lymph Node Staging; The E-Predict Multicenter Study Results
Authors: R. Verhoeven, R. Trisolini, F. Leoncini, M. Bezzi, P. Candoli, A. Messi, M. Krasnik, J. Annema, C. Korte, E. Van Der Heijden
Journal: Journal of Thoracic Oncology (2019)
EP1.01-15 Systemic Hyperinflammation Is a Strong Independent Predictor of Early Mortality in Advanced NSCLC
Authors: J. Isaksson, L. Willén, E. Brandén, H. Koyi, S. Gagatek, A. Berglund, P. Micke, J. Botling
Journal: Journal of Thoracic Oncology (2019)
MA24.03 Factors Impacting Patients’ Worries (Accessing Treatment, Treatment Toxicity, &amp; Emotional Burden) Associated with Lung Cancer Treatments
Authors: U. Basu Roy, S. Janse, E. Janssen, A. Meara, C. Presley, P. Kneuertz, A. Ferris, J. Bridges
Journal: Journal of Thoracic Oncology (2019)
EP1.12-15 Oncologic Treatments and Outcomes for Small-Cell Lung Cancer Patients with Brain Metastases
Authors: J. Bosch-Barrera, A. Hernandez, N. Priego, M. Puigdemont, E. Sais, N. Quer, A. Izquierdo, E. Cuyàs, H. Pla, A. Roqué, V. Garriga, D. Garcia, S. Verdura, A. Roselló, S. Pedraza, J. Brunet, A. Calvo, M. Valiente, J. Menéndez
Journal: Journal of Thoracic Oncology (2019)
EP1.17-26 Spontaneous Right Contralateral Total Pneumothorax in Bullous Lung After Left Pneumonectomy for Lung Cancer
Authors: F. Gradica, L. Lisha, D. Argjiri, A. Cani, F. Kokici, S. Gradica, A. Lala, K. Gradica, L. Shpataraku, G. Quadir
Journal: Journal of Thoracic Oncology (2019)
MA07.08 The Role of a Cachexia Grading System in Patients with NSCLC Treated with Immunotherapy: Implications for Response and Survival
Authors: J. Turcott, A.F. Cardona, L. Ramírez-Tirado, Z.L. Zatarain Barrón, F. Barrón, L. Corrales, C. Martin, P.A. Barragán Castillo, D. Flores-Estrada, A. Ruiz-Patiño, O.G. Arrieta
Journal: Journal of Thoracic Oncology (2019)
EP1.11-03 Diagnostic Evaluation of Patients with Solitary Pulmonary Nodules in a Tertiary Referral Center
Authors: A. Athanasopoulou, I. Gkiozos, V. Skouras, D. Apostolou, V. Kaminitios, P. Nikolopoulos, R. Trigidou, D. Grapsa, E. Kokkotou, K. Syrigos
Journal: Journal of Thoracic Oncology (2019)
Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).
Authors: Deborah A. Thomas, Hagop M. Kantarjian, Farhad Ravandi, Stefan Faderl, Guillermo Garcia-Manero, William Wierda, Alessandra Ferrajoli, Srdan Verstovsek, Dan Jones, Laurie Letvak, Richard Champlin, Jorge Cortes, Susan O’Brien
Journal: Blood (2007)
P1.01-50 Impact of Concomitant HER2 Alterations in Mediating Clinical Outcomes of EGFR-Mutant Patients to Different Generation of EGFR-TKIs
Authors: Y. Cheng, Y. Liu, L. Ma, J. Zhu, C. Yang, L. Zhang, T. Zhang, H. Jiang, Y. Zhang, Y. Wang, J. Hao, L. Zhang, H. Zhang, T. Zhang, J. Lin, L. Shi
Journal: Journal of Thoracic Oncology (2019)
P2.05-13 Impact of Diffusing Capacity for Postoperative Pulmonary Complications in Patients Without Obstructive Pulmonary Disease
Authors: S. Shin, J.H. Cho, H.K. Kim, Y.S. Choi, J. Kim, J.I. Zo, Y.M. Shim, H.Y. Park
Journal: Journal of Thoracic Oncology (2019)
P1.01-96 US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment
Authors: J. Nieva, K. Reckamp, A. Taylor, B. Thakrar, J. Wong, D. Potter, N. Bakker, W. Rubinstein, P. Sun
Journal: Journal of Thoracic Oncology (2019)
P2.09-28 Prognostic Impact of LKB1 Expression in Advanced Non-Small-Cell Lung Cancer
Authors: D.A. Diaz-Garcia, L.A. Ramírez Tirado, A. Aviles-Salas, A.F. Cardona, A. Rodriguez-Rios, F. Barrón, O.G. Arrieta
Journal: Journal of Thoracic Oncology (2019)
P2.04-26 Single Cell Proteomics Profiling of Live T-Cells in KRAS+ and MET-Amp NSCLC to Predict Immune Checkpoint Inhibitor Response
Authors: Z. Lim, X. Wu, M. Hafez, H. Albandar, L. Zhu, H. Yang, S. Mackay, J. Chen, J. Zhou, P. Ma
Journal: Journal of Thoracic Oncology (2019)
MA08.11 SLCG SCAT Trial: Surgical Audit to Lymph Node Assessment Based on IASLC Recommendations
Authors: J.R. Jarabo Sarceda, S. Bolufer, R. Mongil, P. Lopez De Castro, R. Moreno, J.C. Peñalver, R. Embún, J. Pac, F. Algar, P. Gámez, M. Jiménez, G. Sales, E. Pereira, B. Massuti, M. Provencio, F. Hernando-Trancho
Journal: Journal of Thoracic Oncology (2019)
P2.11-22 Comparison of the Sensitivity of USPSTF and PLCOm2012 Lung Cancer Screening Criteria in a Racially Diverse Population
Authors: M. Pasquinelli, M. Tammemägi, K. Kovitz, M. Durham, Z. Deliu, K. Rygalski, L. Liu, M. Koshy, R. Winn, L. Feldman
Journal: Journal of Thoracic Oncology (2019)
Use of altered peptide ligands to modulate immune responses as a possible immunotherapy for allergies
Authors: R. De Palma, G. Sacerdoti, G. F. Abbate, P. Martucci, G. Mazzarella
Journal: Allergy (2000)

Allergies are dramatically increasing in prevalence, and the management of these diseases is a heavy burden on the health‐care systems of developed countries. In recent years, many efforts have been made to improve the therapy of allergies and to develop new approaches for immunotherapy. Here we briefly review the use of peptides to modulate T‐cell responses to allergens. We focus mainly on the possibility of using altered peptide ligands (APLs), i.e., peptides tailored on immunodominant T epitopes and bearing a single amino‐acid substitution, as a tool to modulate immune responses to allergens. These peptides may be recognized by the specific T cells triggered by the agonist peptides, but they are unable to elicit T‐cell responses; thus, they could be ideal candidates to modulate immune responses to allergens. The availability of these peptides could allow new approaches for immunotherapies.
MA10.10 Uptake in Lung Cancer Screening – Does CT Location Matter? A Pilot Study Comparison of a Mobile and Hospital Based CT Scanner
Authors: E. Bartlett, S. Kemp, S. Desai, S. Mirsadraee, C. Ridge, J. Morjaria, P. Shah, K. Morris, J. Derbyshire, M. Chen, C. Peacock, N. Ivashniova, M. Martins, J. Addis, S. Padley, A. Devaraj
Journal: Journal of Thoracic Oncology (2019)
P1.01-83 Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients
Authors: R. Doebele, L. Perez, H. Trinh, M. Martinec, R. Martina, T. Riehl, M. Krebs, N. Meropol, W. Wong, G. Crane
Journal: Journal of Thoracic Oncology (2019)
Extracellular pH modulating injectable gel for enhancing immune checkpoint inhibitor therapy
Authors: Hyung-seung Jin, Da-som Choi, Minkyung Ko, Dongkap Kim, Dong-hee Lee, Soojin Lee, Ah Young Lee, Seung Goo Kang, Soo Hyun Kim, Youngmee Jung, Youngdo Jeong, Justin J. Chung, Yoon Park
Journal: Journal of Controlled Release (2019)

Clinical data from diverse cancer types shows that the increased T cell infiltration in tumors correlates with improved patient prognosis. Acidic extracellular pH is a major attribute of the tumor microenvironment (TME) that promotes immune evasion and tumor progression. Therefore, antagonizing tumor acidity can be a powerful approach in cancer immunotherapy. Here, Pluronic F-127 is used as a NaHCO3 releasing carrier to focally alleviate extracellular tumor acidity. In a mouse tumor model, intratumoral treatment with pH modulating injectable gel (pHe-MIG) generates immune-favorable TME, as evidenced by the decrease of immune-suppressive cells and increase of tumor infiltrating CD8 + T cells. The combination of pHe-MIG with immune checkpoint inhibitors, anti-PD-1 and anti-TIGIT antibodies, increases intratumoral T cell function, which leads to tumor clearance. Mechanistically, extracellular acidity was shown to upregulate co-inhibitory immune checkpoint receptors and inhibit mTOR signaling pathways in memory CD8 + T cells, which impaired effector functions. Furthermore, an acidic pH environment increased the expression and engagement of TIGIT and its ligand CD155, which suggested that the extracellular pH can regulate the suppressive function of TIGIT pathway. Collectively, these findings suggest that pHe-MIG holds potential as a new TME modulator for effective immune checkpoint inhibitor therapies.
Responding to global stimulant use: challenges and opportunities
Authors: Michael Farrell, Natasha K Martin, Emily Stockings, Annick Bórquez, Javier A Cepeda, Louisa Degenhardt, Robert Ali, Lucy Thi Tran, Jürgen Rehm, Marta Torrens, Steve Shoptaw, Rebecca McKetin
Journal: The Lancet (2019)
P1.10-06 Pathological Characterization of Radon-Induced Lung Cancer in Rats
Authors: L. Mezquita, J. Adam, D. Planchard, C. Jovelet, E. Rouleau, E. Auclin, C. Naltet, P. Lavaud, L. Lacroix, S. Chevillard, B. Besse
Journal: Journal of Thoracic Oncology (2019)
P2.11-04 Longitudinal Surveillance of Circulating Tumor Cell in Patients Who Presented with Resectable Pulmonary Lesion Suspicious Malignancy
Authors: C.Y. Wu, C. Lee, C.F. Wu, J.Y. Fu, C.T. Wen, Y.H. Liu, H. Liu, C.H. Hsieh
Journal: Journal of Thoracic Oncology (2019)
P2.04-13 Interleukin-18 and Lung Cancer: A Mendelian Randomization Study
Authors: J. Liu, H. Zhou, Y. Zhang, W. Fang, Y. Yang, S. Hong, G. Chen, S. Zhao, Z. Zhang, J. Shen, W. Xian, Y. Huang, H. Zhao, L. Zhang
Journal: Journal of Thoracic Oncology (2019)
EP1.16-39 Prospective Epidemiological Study of Metastatic Non-Small Cell Lung Cancer (NSCLC) in Latin America – LATINO Lung (LACOG 0116)
Authors: G. Werutsky, A.F. Cardona, D. Kaen, O.G. Arrieta, A. Gelatti, C. Mathias, M. Zukin, E. Cronemberger, E. Mascarenhas, C. Campos, V. Cordeiro De Lima, G. Borges, J. Coelho, F. Oliveira, A. Silva, L.H. Araújo, A. Quiroba, H. Andrade, I. Morbeck, J. Lobaton, J. Dias, J. Zarba, L. Fein, P. Salman, R. Trejo, C. Barrios
Journal: Journal of Thoracic Oncology (2019)
P2.14-59 Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)
Authors: P. Cheema, A. Passaro, C. Martin, M. Tiseo, K. Park, G. Chang, Y. Hu, B.C. Cho, M. Miranda, A. Fernandes, H. Freitas
Journal: Journal of Thoracic Oncology (2019)
Cystic fibrosis drugs to be available on NHS in England within 30 days
Authors: Zosia Kmietowicz
Journal: BMJ (2019)

Every patient in England with cystic fibrosis who could benefit from one of the new precision drugs that target certain mutations underlying the condition will have access to them within 30 days, NHS England has said after striking a deal with the US manufacturer Vertex Pharmaceuticals.

NHS England has been trying to secure access to Orkambi (a combination of lumacaftor and ivacaftor), Symkevi (tezacaftor and ivacaftor), and Kalydeco (ivacaftor) for more than 18 months. Pressure mounted last month after the Scottish government negotiated a confidential discount with Vertex to make Orkambi available to 400 patients.1

Vertex had wanted £105 000 (€123 000; $138 000) per patient for Orkambi. Last July it rejected what NHS England said was a “fair and final offer” of around £500m over five years …
MA17.10 Lactate Transporter Blockade as a Strategy to Overcome VEGF Inhibitor-Resistance in LKB1-Deficient NSCLC
Authors: I. Guijarro, A. Poteete, S. Cho, T. Zhou, Y. Fan, E. Roarty, M. Nilsson, E. Parra, B. Mino, I. Wistuba, J. Wang, F. Skoulidis, J. Heymach
Journal: Journal of Thoracic Oncology (2019)
Periumbilical Papules in a Middle-aged Woman
Authors: Tejas Vishwanath, Angela Nagpal, Geeta Shinde
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
P2.14-35 2-Deoxy-D-Glucose Sensitizes Non-Small Cell Lung Cancer with EML4-ALK Fusion to Crizotinib via Suppression of HK2 Through AKT/mTOR Passway
Authors: C. Lin, H. Yong, C. Lu, Y. Song, H. Chen, L. Li
Journal: Journal of Thoracic Oncology (2019)
In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924
Authors: Raphael Koch, Amanda L Christie, Noriaki Yoshida, Samuel Y. Ng, Kay Shigemori, Sara N Morrow, Alexandria Van Scoyk, Steven M. Horwitz, Eric Jacobsen, Solimar Santiago, Jian-Guo Ren, Vincent Guerlavais, D. Allan Annis, Manuel A. Aivado, David M. Weinstock
Journal: Blood (2017)
Taking the Heat: Potential Fetal Health Effects of Hot Temperatures
Authors: Lindsey Konkel
Journal: Environmental Health Perspectives (2019)

Exposure to periods of extreme heat has been linked to a variety of adverse health outcomes, including cardiovascular disease, respiratory diseases, kidney disease, and mental illness. 1,2Now researchers are investigating the potential effects of heat exposure in the fetus.Several epidemiological studies over the past five years have reported associations between high temperatures and adverse pregnancy outcomes, including preterm birth, stillbirth, and low birth weight (LBW), 3,4 as well as congenital heart defects. 5(At least two studies have also examined ambient temperature in relation to neural tube defects. 6,7) Each study has its strengths, weaknesses, and caveats, but experts point toward the consistent and concerning signal that's starting to materialize in the literature."When more and more studies start to pile up and coalesce around the same conclusion, we have to pay attention, especially when there's biological plausibility behind the outcome," says Nathaniel DeNicola, an obstetrician-gynecologist at the George Washington University Hospital in Washington, DC, and environ-mental health expert for the American College of Obstetricians and Gynecologists.Although this area of research is relatively new, obstetricians have long known that natural gestational changes in thermoregulation can make pregnant women vulnerable to heat exposure. 3,8eight gained during pregnancy lowers the ratio of body surface area to body mass, which may make it harder for pregnant women to dissipate internal heat. 9The metabolic demands of the growing fetus may create heat, leading to a slight increase in a pregnant woman's core body temperature. 9Pregnant women are also more susceptible to dehydration, which in the late stages of pregnancy could trigger uterine contractions and, potentially, early labor. 10owever, beyond these basic physiological changes, exactly how maternal heat exposure might contribute to birth defects or adverse obstetrical outcomes is not yet clear.The mechanism would likely differ for different outcomes, say researchers.Animal studies suggest that heat exposure during early pregnancy could interfere with normal protein synthesis through the Taken together, a growing body of evidence hints at a spectrum of heat-related vulnerabilities across pregnancy.Some studies have suggested that heat exposures in the first trimester, when the major organs form, could contribute to certain birth defects, whereas exposure in the second or third trimester, when the fetus undergoes rapid growth, may contribute to preterm birth or stillbirth.Heat exposure throughout pregnancy may contribute to low birth weight.
P2.01-70 Therapy with Osimertinib in Patients with T790M Mutation: Experience of a Portuguese Oncology Center
Authors: I. Azevedo Pereira, I. Vieira, A. Rodrigues, I. Pousa, J. Oliveira, M. Cassiano, C. Oliveira, A. Rosinha, I. Azevedo, M. Soares
Journal: Journal of Thoracic Oncology (2019)
Osteoblastic Activation and Response to Velcade® in Patients with Relapsed/Refractory Multiple Myeloma (MM).
Authors: Maurizio Zangari, Choon-Kee Lee, Bart Barlogie, Kevin Najarian, Seung-Hee Kang, Shmuel Yaccoby, Dixie Esseltine, Julie M. Stover, Guido J. Tricot
Journal: Blood (2004)
High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories.
Authors: Francesca Novara, Luca Arcaini, Michele Merli, Francesco Passamonti, Silvia Zibellini, Francesca Montanari, Silvia Rizzi, Elisa Rumi, Cristiana Pascutto, Marco Paulli, Orsetta Zuffardi, Mario Lazzarino
Journal: Blood (2007)